The Southern African Journal of Gynaecological Oncology (SAJGO) is the official journal of the South African Society of Gynaecologic Oncology (SASGO) and the South African Society of Clinical and Radiation Oncology (SASCRO).

The Journal aims to be the prime journal on women’s cancer for local healthcare workers and gynaecologists, focusing on all aspects of cancer prevention, detection, diagnosis and treatment. The SAJGO is also a specialist journal catering for sub-specialist gynaecologic oncologists, for other specialists with a specific interest in breast and gynaecologic cancer, including medical oncologists, radiation oncologists, surgeons, radiologists, pathologists, geneticists, specialised nurses and research scientists.

The Journal supports the vision of SASGO, namely to promote excellence in gynaecologic cancer care and will also aim to promote excellence in breast cancer care. The Journal also supports the mission of the society and will assist SASGO with all aspects of communication, training, advocacy and by supporting and stimulating local research.

Jardiance Declared Best International Pharmaceutical Product 2018

Jardiance Declared Best International Pharmaceutical Product 2018 Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best...

Maternal mortality – Fact Sheet

Maternal mortality - Fact SheetMSD for Mothers     Global statistics1 • Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth. • 99% of all maternal deaths occur in developing countries. • Maternal mortality is...

CIPLA LAUNCHES NEW TRIPLE-COMBINATION ANTIRETROVIRAL DRUG, REYDIN

Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla is launching its new triple-combination ARV treatment for HIV in South Africa.

Empagliflozin proven to improve clinical outcomes in real world practice across a broad spectrum of cardiovascular risk

The most recent 2018 treatment recommendations from the American Diabetes Association are that, after considering drug specific and patient factors, treatment for people with atherosclerotic cardiovascular disease (ASCVD) should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and/or cardiovascular mortality.

Skin protection range, Dexeryl, receives Allergy Foundation’s seal of approval

Partnership brings established international brand to South African consumers with complementary barrier and cleansing presentations for dry skins.

SAJGO (July 2016 – June 2017) | 1 142

Wildcard SSL